U.S. Inflammatory Bowel Disease Market.pdf

April 2021
Copyright © PROPHECY MARKET INSIGHTS 2021, All Rights Reserved
U.S. Inflammatory Bowel Disease Market :
Industry, Size, Share, Growth, Trends and
Forecast, 2019–2029

Chapter 4: U.S. Inflammatory Bowel Disease Market
, By Type
Report Snippet
Copyright © PROPHECY MARKET INSIGHTS 2021, All Rights Reserved 2
Chapter 1 : Table of Contents
Chapter 3: Market Dynamics
Chapter 2: Market Purview
, By Treatment Type
, By Distribution Channel
, By Region
Chapter 8: Company Profiles
Investment Outlook Future of the Market

Table of Contents

Table of Content
Sr. No. Content
1.0 Chapter 1
Research Methodology
Research Objective and Assumption
Research Process
Scope & Coverage
Currency Conversion Rate
2.0 Chapter 2
2.1 Market Purview
2.2 Executive Summary
Market Snippet, By Type
Market Snippet, By Treatment Type
Market Snippet, By Distribution Channel
Market Snippet, By Region
Opportunity Map Analysis
3.0 Chapter 3
Drivers

Table of Content
Sr. No. Content
Restrains
Opportunities
Trends
DR Impact Analysis
Porter’s Five Forces Analysis
COVID-19 Impact on the Market
Key Highlights
Challenges
4.0 Chapter 4
4.0.1 U.S. Inflammatory Bowel Disease Market Value (US$ Bn), By Type
Segment Overview
Market Value and Forecast (US$ Bn), and Share (%) Analysis, 2018 – 2029
Y-o-Y Growth (%) Analysis, 2019 – 2029
4.1 Crohn's Disease
Overview
Market Value and Forecast (US$ Bn), and Y-o-Y Growth (%) Analysis, 2018 – 2029

Table of Content
Sr. No. Content
4.2 Ulcerative Colitis
Overview
5.0 Chapter 5
5.0.1 U.S. Inflammatory Bowel Disease Market Value (US$ Bn), By Treatment Type
Segment Overview
Y-o-Y Growth (%) Analysis, 2019 – 2029
5.1 Injectables
Overview
5.2 Oral
Overview
5.3 Surgery
Overview

Table of Content
Sr. No. Content
6.0 Chapter 6
6.0.1 U.S. Inflammatory Bowel Disease Market Value (US$ Bn), By Distribution Channel
Segment Overview
6.1 Hospital Pharmacy
Overview
Market Value and Forecast (US$ Bn), 2018 – 2029
6.2 Retail Pharmacy
Overview
6.3 Online Pharmacy
Overview
8.0 Chapter 8
8.0.1 Company Profiles

Table of Content
Sr. No. Content
8.1 Abbott Laboratories
Company Overview
Product Portfolio
Key Highlights
Financial Overview
Business Strategies
SWOT Analysis
8.2 AbbVie Inc.
Company Overview
Product Portfolio
Key Highlights
Financial Overview
Business Strategies
SWOT Analysis
8.3 Celgene Corp.
Company Overview

Table of Content
Sr. No. Content
Product Portfolio
Key Highlights
Financial Overview
Business Strategies
SWOT Analysis
8.4 Eli Lilly and Co.
Company Overview
Product Portfolio
Key Highlights
Financial Overview
Business Strategies
SWOT Analysis
8.5 Johnson & Johnson Services Inc.
Company Overview
Product Portfolio
Key Highlights

Table of Content
Sr. No. Content
Financial Overview
Business Strategies
SWOT Analysis
8.6 Johnson & Johnson Services Inc.
Company Overview
Product Portfolio
Key Highlights
Financial Overview
Business Strategies
SWOT Analysis
8.7 Laboratory Corporation of America Holdings
Company Overview
Product Portfolio
Key Highlights
Financial Overview
Business Strategies

Table of Content
Sr. No. Content
SWOT Analysis
8.8 Pfizer Inc.
Company Overview
Product Portfolio
Key Highlights
Financial Overview
Business Strategies
SWOT Analysis
8.9 Takeda pharmaceutical Co.
Company Overview
Product Portfolio
Key Highlights
Financial Overview
Business Strategies
SWOT Analysis
8.10 Sanofi S.A.

Table of Content
Sr. No. Content
Company Overview
Product Portfolio
Key Highlights
Financial Overview
Business Strategies
SWOT Analysis
9.0 Chapter 9
Investment Outlook
10.0 Chapter 10
Appendix
Abbreviation

About Us
13

About Us
14
Who we are:
Prophecy is a specialized market research, analytics, marketing
and business strategy, and service offerings company that offer
strategic and tactical support to clients for making well-informed
business decisions and to identify and achieve high value
opportunities in the target business area. Also, we help our client
to address business challenges and provide best possible Service
Offerings to overcome them and transform their business.
Prophecy’s expertize area covers types, applications, latest
trends, developments, market growth factors, and challenges
along with market forecast in various business areas such as
Healthcare, Pharmaceutical, Biotechnology, Information
Technology (IT), Hospitals, Small and Ownership Model-sized
enterprises (SMEs), Chemical, Agriculture, Food and Beverage,
Energy, and Oil and Gas. We also offer various other Adaptive
Pants such as, data mining, information management, and
revenue enhancement suggestions.
Source: Prophecy Market Insights
We are a team of dedicated and impassioned individuals,
who believe strongly in giving our very best to what we do
and we never return down from any challenge. At prophecy
we cater to industries, individuals, and organizations across
the globe and deliver our offerings in the shortest possible
turnaround time.
Our well defined approach ensures our clients will receive
unique competitive advantage, and secure and long lasting
results.
“WE BELIEVE IN LONG–TERM BUSINESS
RELATIONS FOR GROWTH AND SUCCESS”

A rich repository of syndicated
reports across 8 Industries
Dedicated Analyst
Working
More than 100+ Clients
worldwide including various
Fortune 500 Companies
Pioneer in adopting best
research practices to ensure
deeper insights
Top leadership having more
than
50 man years of experience
across varied industries
2+ years of industry
experience in delivering
valuable research Insights at
Global, Regional and Country
Level
About Us

Collection
of
Data
Collaboration
of Data
Identification
of data
Evaluation of
Market
Dynamics
Verification
and Analysis
2.This process consists
of gathering data,
accessing proprietary
databases, and reaching
out to key industry
participants that
operate in the market
across the value chain.
It also involves studying
several patterns in
the historical data and
comparing it with the
current scenario.
4. This is the final stage,
which involves both
quantity and quality
checks. Although the
process of data
verification is an integral
part of the research
process, all data points
and statistics and figures
are re-checked to uphold
their authenticity and
validity.
3.This stage involves the
validation of data and
arrival at actual statistics,
and evolution of the
market over the years. It
entails the study and
analyzes various segments
and Applications of the
market. An impact analysis
is also performed to
observe which factors will
affect the market in the
next few years.
1. This step involves identification of several primary
and secondary data research sources, including
Prophecy internal data sources.
The primary sources consist of in-depth discussions
and interviews with policy makers, industry experts,
and data evaluators, whereas secondary sources
include a thorough study of market journals, press
releases, annual reports, and Pharmaceuticals and
non Pharmaceuticals agencies websites.
This phase includes a detailed evaluation of several
factors that are likely to affect the market dynamics.
It involves a comprehensive assessment of major
market pain points, drivers, and trends.

Research Objective
To predict the
size of the
market
To offer wide ranging market
statistics with a detailed
classification along with the
market size of each segment
To analyze key
strengths,
opportunities,
and strategies of
major
companies
To outline and forecast the
Governance, Risk Management and
Compliance (GRC) market in globally
based on segmentation and region
To study market
opportunities for
participants and
stakeholders by
identifying high
growth sectors in
the market
To provide comprehensive
information about factors that affect
market dynamics
To analyze several micro-market
indicators considering growth
factors, market prospects, and
strategic market contribution
To examine competitive scenarios
such as collaborations, mergers and
acquisitions, R&D activities, and
advanced developments

Research Process
PROJECT
SCOPE
PROJECT
KICKOFF
PRELIMINARY
RESEARCH
MARKET
ANALYSIS &
SEGMENTATION
REPORT
SYNTHESIS
REPORT
DELIVERY
POST-SALE
SERVICE

U.S. Market Size
Market/Revenue share of each key player in each
Type segment
Market/Revenue share of each key player in the
U.S. market
Bottom-up Approach –
Collection of market related data and information
from primary and secondary sources, and data
analysis.
Primary Sources:
 Demand Side Key Opinion Leaders
 Supply Side Key Opinion Leaders
Secondary Sources:
 Annual Reports
 Financial Reports and Presentations
 Press Releases
 Research Journals
 Paid Data Sources
Market/Revenue share split by each market segment
such as By Type Fracturing Fluids/Fracturing Fluids
sector/end user
Market/Revenue share split by each region and
country in the U.S. market
Top-down Approach –
Market size and analysis validation through primary
and secondary research participants and key opinion
leaders.
Primary Sources:
 Demand Side Key Opinion Leaders
 Supply Side Key Opinion Leaders
Secondary Sources:
 Annual Reports
 Financial Reports and Presentations
 Press Releases
 Research Journals
 Paid Data Sources

Definition and Scope – Prophecy Market Insights provide the market definition to
understand the target Type/service and provide the market scope to understand
the report coverage after thoroughly understanding of target market and market
specific requirements.
Primary Research – We formulates a detailed discussion guide to perform primary
research. In primary research collection of data is performed through telephonic
interview, E-mail questionnaire’s, and in-depth discussion with industry experts,
manufacturers, suppliers, and distributors. The primary research participant
includes but not limited to CEO’s, Managers, Directors, VP’s, Suppliers, CSO’s, and
etc.
Secondary Research – Our research analyst performs in-depth secondary research
and extensive data mining to collect market related information through various
authentic data sources such as Annual Reports, Trade Publications, Magazines,
Research Publications, Company Press Release, and some paid data sources.
In-house Data Analysis – After extensive data mining, we perform in-house market
analysis by using various data tools, statistical methods, and data analysis tools to
arrive on a conclusion and reduce the margin of error. We provide our overviews
and market forecast for the target market after thoroughly understanding and
analyzing of collected data, historic market trends, and research outputs.
Report Delivery – Prophecy Market Insights provide report in required electronic
format (preferably in PDF format), as PDF format is easy to read and present.

Preface

Scope & Coverage
2019 2020 2021-2029
Base Year Estimated Year Forecast Years
The report considers 2019 as the base year. All calculations involving quantitative data are
based on 2019. The values represented in the report are actual values for 2019, whereas,
the values are estimated for the period 2020−2029.

Market Segmentation
U.S. Inflammatory Bowel Disease Market
By Type By Region
 North America
 Europe
 Asia Pacific
 Latin America
 Middle East & Africa
 Crohn's Disease
 Ulcerative Colitis
 Injectables
o TNF-inhibitors
o IL inhibitors
o Anti-integrin
o Others
 Oral
o ASAs
o Corticosteroids
o JAK inhibitors
o Others
 Surgery
By Treatment Type
 Hospital Pharmacy
 Retail Pharmacy
 Online Pharmacy
By Distribution Channel

Currency Conversion
Currency Conversion 2013-2018
The standard currency used throughout the report is USD ($). However, in the case of other currencies, the annual average currency rate
(January 1 to December 31) is used for conversion. These conversion rates are rounded to the nearest decimal place. The chart below
represents the standard conversion rates used in the report.
Currency Conversion 2013 2014 2015 2016 2017 2018
$/€ USD/EUR 0.7532 0.7535 0.8969 0.8988 0.8605 0.8566
$/£ USD/GBP 0.6395 0.6072 0.6526 0.7309 0.7607 0.7586
$/¥ USD/JPY 98.58 105.84 120.9 107.5269 113.8867 111.0019
$/₭ USD/SEK 6.5127 6.8587 8.404 8.9328 8.4135 8.8826
$/A$ USD/AUD 1.0362 1.1094 1.3112 1.343 1.3042 1.3578
$/¥ USD/RMB (CNY) 6.1905 6.1432 6.1606 6.61 6.6294 6.6675

Market Purview
Chapter 02
2
5

Executive Summary (1/9)
26
Overview
 Prophecy Market Insights forecasts the Bowl Disease market size to grow from USD XX billion in 2019 to USD XX billion by 2024, at a
Compound Annual Growth Rate (CAGR) of XX% during the forecast period.

27
Table 2.1: U.S. Inflammatory Bowel Disease Market Overview
Parameters 2019 (E) 2029 (F)
U.S. Inflammatory Bowel Disease Market Value (US$ Bn) Xx Mn Xx Mn| CAGR: 13.7% |
By Type Segment with Largest Value (US$ Bn) Crohn's Disease: XX Crohn's Disease: XX
By Type Segment with Highest CAGR (%)-2019-2029 CAGR- XX%
By Treatment Type Segment with Largest Value (US$ Bn) Injectables: XX Injectables: XX
By Treatment Type Segment with Highest CAGR (%)-2019-
2029
CAGR-XX%
By Distribution Channel with Largest Value (US$ Bn) Hospital Pharmacy: XX Hospital Pharmacy: XX
By Distribution Channel Segment with Highest CAGR (%)-
2019-2029
CAGR- XX%
To be Continued …

28
Table 2.2: U.S. Inflammatory Bowel Disease Market Overview
Parameters 2019 (E) 2029 (F)
By Region with Largest Value (US$ Bn) Asia Pacific : XX Asia Pacific xx
By Region with Highest CAGR (%)-2019-2029 CAGR- XX%
Key Market Players:
Abbott Laboratories, AbbVie Inc., Celgene Corp., Eli Lilly and Co.,
Johnson & Johnson Services Inc., Laboratory Corporation of America
Holdings, Pfizer Inc.,Takeda pharmaceutical Co. and Sanofi S.A..

29
Description
Figure 2.1: U.S. Inflammatory Bowel Disease Market Value Share (%), By
Type – 2020 (E)
Analysis
Crohn's Disease
Ulcerative Colitis
 Prophecy Market Insights forecasts the Bowl Disease market size
to grow from USD XX billion in 2019 to USD XX billion by 2024, at a
Compound Annual Growth Rate (CAGR) of XX% during the forecast
period.
 The factors such as the significant prevalence of IBD such as
Crohn’s disease and ulcerative colitis across the country
contributing to the market growth.
 Crohn’s disease segment is estimated to dominate the
market. The growth of the segment is attributed to the
comparatively higher incidence of Crohn’s disease than
ulcerative colitis. For Crohn’s and ulcerative colitis, the
development of minimally invasive methods has been evolved
with more caution as compared to other colorectal diseases.
This is primarily due to disease-related characteristics that are
concerned with IBD

Injectables
Oral
Surgery
Figure 2.2: U.S. Portable
Analysis and Outcome
Treatment Type – 2020 (E)
Region – 2019 (E
Distribution Channel - 2020(E)
Hospital Pharmacy
Retail Pharmacy
Online Pharmacy

Description
Region – 2020 (E)
U.S.
 The US IBD therapeutics market is estimated to grow significantly
at a CAGR of around XX% during the forecast period. The factors
such as the significant prevalence of IBD such as Crohn’s disease
and ulcerative colitis across the country contributing to the market
growth. As per the Centers for Disease Control and Prevention
(CDC), the prevalence of Crohn’s disease and ulcerative colitis in
the US was 201 and 238 per 100,000 population respectively in
2015. Moreover, the CDC also estimates the incidence rate of types
of IBD across the country. As per the CDC, the incidence of Crohn’s
disease and ulcerative colitis were nearly 14.6 and 14.3 per
100,000 population respectively in 2015. Additionally, according to
the aforementioned organization, the percentage of people
diagnosed with IBD (either Crohn’s disease or ulcerative colitis)
increased from 0.9% of US adults in 1999 to 1.3% of US adults in
2015. This percentage is further expected to expand in the near
future; thereby, promising significant growth for the IBD market
during the forecast period. .

Market Dynamics
Chapter 03

Drivers (1/4)
Significant prevalence of IBD such as Crohn's disease and ulcerative colitis
 As per the Centers for Disease Control and Prevention (CDC), the prevalence of Crohn's disease and ulcerative colitis in the US was 201
and 238 per 100,000 population respectively in 2015. Moreover, the CDC also estimates the incidence rate of types of IBD across the
country.

Drivers (2/4)
Emergence of biosimilars
 For instance, in 2016, the U.S. FDA approved a biosimilar Inflectra, which is similar to Remicade with lower
competitive pricing. Remicade, a biologic drug manufactured by Janssen Non-surgical and approved in 1998,
is majorly used for the treatment of Crohn’s disease and ulcerative colitis.

Drivers (3/4)
Presence of strong pipeline products for the treatment of inflammatory bowel disease (IBD)

Drivers (4/4)
XXX

Restraint (1/2)
High cost of treatment

Opportunity
Development of advanced technologies to tap niche markets

Challenge
XX

Pipeline Analysis
Launching of new products
 Pipeline products such as Upadacitinib, Ozanimod, and Risankizumab are estimated to have better mechanism of action and
efficacy.
 Presence of strong pipeline products for the treatment of inflammatory bowel disease (IBD) is anticipated to drive the market over
the forecast period.
 Ulcerative colitis is estimated to be the fastest growing segment over the forecast year owing to presence of strong pipeline
products for its treatment.
 In March 2019, Johnson & Johnson Services Inc. announced new data from its Phase III UNIFI study showing positive results of
STELARA in adults suffering from moderate to severe ulcerative colitis.

Drivers and Restraints Impact Analysis
Low High
Low
High
Impact on Market Value
Likely
Growth
Impact
on
Market
Growth
Rate
D1
Drivers
Restraints
High cost of treatment
R1
D2
Significant prevalence of IBD such
as Crohn's disease and ulcerative
colitis
Emergence of biosimilars
XXX
R2
D3
Presence of strong pipeline
products for the treatment of
inflammatory bowel disease (IBD)
D4 XXX

PORTER’S FIVE FORCES ANALYSIS
Analysis
 The Porter’s five forces model studies the five identified
competitive forces that shape every industry and market, in
order to determine the intensity of the competition, and
thus, the profitability and attractiveness of the industry.
 The objective of the growth strategy is to adapt to these
competitive forces in a manner that may improve the
position of the organization. This study includes an
exhaustive Porter’s five forces framework, incorporating
the factors influencing each force, to analyze the market
from a microeconomic perspective.
 In the study, Porter’s five forces are analyzed considering
the factors influencing each force and quantifying the
factors, through primaries and quantitative analysis. The
quantified factors are further mapped out, to derive the
impact of each force on competitive dynamics.
Outcome
COMPETITIVE
RIVALRY
High

PORTER’S Five Forces Analysis
05
Threat of New
Entrants
Medium
01
02
03
Threats of
Substitutes
High
04
Buyer Power
High
Supplier Power
High
Competitive Rivalry
High

Key Highlights
02 03 04
01
 In March 2019,
Johnson &
Johnson Services
Inc. announced
new data from its
Phase III UNIFI
study showing
positive results of
STELARA in adults
suffering from
moderate to
severe ulcerative
colitis.

Key Highlights
06 07 08
05

U.S. Inflammatory Bowl Disease Market, By
Type
Chapter 04

Table 4.1: U.S. Inflammatory Bowel Disease Market Value and Forecast (US$ Bn), By Type - 2019–2029
U.S. Bowl Disease Market, By Type
Product Type 2019 H 2020 F 2021 F 2022 F 2023 F 2024 F 2025 F 2026 F 2027 F 2028 F 2029 F
CAGR
(2018–
29)
Crohn's Disease XX XX XX XX XX XX XX XX XX XX XX XX
Ulcerative Colitis XX XX XX XX XX XX XX XX XX XX XX XX
Total XX XX XX XX XX XX XX XX XX XX xx Xx

U.S. Inflammatory Bowel Disease Market , By Type
Figure 4.1 : U.S. Inflammatory Bowel Disease Market Value and Forecast (US$ Bn), and Y-o-Y
Growth (%), By Type - 2018-2029
 The U.S. Inflammatory Bowel Disease Market was valued by
US$xx Mn in 2019 and is expected to reach US$xxMn in 2029,
and register a CAGR of xx% over the forecast period
 The first five year (2019-2023) cumulative value is projected to
be US$XXBn, as compared to relatively higher cumulative
value of US$XXBn for the last five year (2024-2028) of the
forecast period.
Analysis and Outcome
XXx: Projected growth between 2019 and 2029
0.0%
0.1%
0.2%
0.3%
0.4%
0.5%
0.6%
0.7%
0.8%
0.9%
1.0%
1.1%
1.2%
1.3%
1.4%
1.5%
1.6%
1.7%
1.8%
1.9%
2.0%
2.1%
2.2%
2.3%
2.4%
2.5%
2.6%
2.7%
2.8%
2.9%
3.0%
3.1%
3.2%
3.3%
3.4%
3.5%
3.6%
3.7%
3.8%
3.9%
4.0%
4.1%
4.2%
4.3%
4.4%
4.5%
4.6%
4.7%
4.8%
4.9%
5.0%
5.1%
5.2%
5.3%
5.4%
5.5%
5.6%
5.7%
5.8%
5.9%
6.0%
6.1%
6.2%
6.3%
6.4%
6.5%
6.6%
6.7%
6.8%
6.9%
7.0%
7.1%
7.2%
7.3%
7.4%
7.5%
7.6%
7.7%
7.8%
7.9%
8.0%
8.1%
8.2%
8.3%
8.4%
8.5%
8.6%
8.7%
-
500.0
1,000.0
1,500.0
2,000.0
2,500.0
2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029
Value Y-O-Y

Crohn's Disease

Crohn's Disease
Figure 4.2: U.S. Inflammatory Bowel Disease Market Value and Forecast (US$ Bn), and Y-o-Y
Growth (%), By Crohn's Disease 2018-2029 Analysis and Outcome
Xx: Projected growth between 2019 and 2029
0.0%
0.1%
0.2%
0.3%
0.4%
0.5%
0.6%
0.7%
0.8%
0.9%
1.0%
1.1%
1.2%
1.3%
1.4%
1.5%
1.6%
1.7%
1.8%
1.9%
2.0%
2.1%
2.2%
2.3%
2.4%
2.5%
2.6%
2.7%
2.8%
2.9%
3.0%
3.1%
3.2%
3.3%
3.4%
3.5%
3.6%
3.7%
3.8%
3.9%
4.0%
4.1%
4.2%
4.3%
4.4%
4.5%
4.6%
4.7%
4.8%
4.9%
5.0%
5.1%
5.2%
5.3%
5.4%
5.5%
5.6%
5.7%
5.8%
5.9%
6.0%
6.1%
6.2%
6.3%
6.4%
6.5%
6.6%
6.7%
6.8%
6.9%
7.0%
7.1%
7.2%
7.3%
7.4%
7.5%
7.6%
7.7%
7.8%
7.9%
8.0%
8.1%
8.2%
8.3%
8.4%
8.5%
8.6%
8.7%
-
500.0
1,000.0
1,500.0
2,000.0
2,500.0
2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029
Value Y-O-Y

Ulcerative Colitis

Ulcerative Colitis
Figure 4.3: U.S. Inflammatory Bowel Disease Market Value and Forecast (US$ Bn), and Y-o-Y
Growth (%), By Ulcerative Colitis- 2018-2029 Analysis and Outcome
2.1.x: Projected growth between 2019 and 2029
 The U.S. Inflammatory Bowel Disease Market by Ulcerative
Colitiswas valued US$xxBn in 2019 and is expected to reach
US$xxBn in 2029, and register a CAGR of xx% over the forecast
period
 The first five year (2019-2023) cumulative value is projected to
be US$xxBn, as compared to relatively higher cumulative value
of US$xxBn for the last five year (2024-2028) of the forecast
period.
0.0%
0.1%
0.2%
0.3%
0.4%
0.5%
0.6%
0.7%
0.8%
0.9%
1.0%
1.1%
1.2%
1.3%
1.4%
1.5%
1.6%
1.7%
1.8%
1.9%
2.0%
2.1%
2.2%
2.3%
2.4%
2.5%
2.6%
2.7%
2.8%
2.9%
3.0%
3.1%
3.2%
3.3%
3.4%
3.5%
3.6%
3.7%
3.8%
3.9%
4.0%
4.1%
4.2%
4.3%
4.4%
4.5%
4.6%
4.7%
4.8%
4.9%
5.0%
5.1%
5.2%
5.3%
5.4%
5.5%
5.6%
5.7%
5.8%
5.9%
6.0%
6.1%
6.2%
6.3%
6.4%
6.5%
6.6%
6.7%
6.8%
6.9%
7.0%
7.1%
7.2%
7.3%
7.4%
7.5%
7.6%
7.7%
7.8%
7.9%
8.0%
8.1%
8.2%
8.3%
8.4%
8.5%
8.6%
8.7%
-
500.0
1,000.0
1,500.0
2,000.0
2,500.0
2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029
Value Y-O-Y

Company Profiles
Chapter 09

Abbott Laboratories
Company Overview Business Overview
Source: Company Annual Reports and Website
Established 1902
Key Management Mike Roman (CEO)
Private/Public Public
Headquarter Minnesota, U.S.
Headcount 96,000 (2019)
Geographic Presence
North America, Europe, Asia
Pacific, Middle East & Africa, and
Latin America
Total Value (US$ Bn) 32,136 (2019)
Value Growth (%) Over
Previous Year
-0.01
Key Applications
Adhesives, ceramics, filtration
products, closure systems for
personal hygiene products, acoustic
system products, automotive
components, abrasion-resistant
films, structural
adhesives; and paint finishing and
detailing products
Website www.3m.com
Hidden for
Sample

Abbott Laboratories
28,500
29,000
29,500
30,000
30,500
31,000
31,500
32,000
32,500
33,000
2016 2017 2018 2019
Company Financial (US$ Bn) Overview, by Year Analysis and Outcome

Key Highlights
02 03 04
01

Business Strategies Overview
Abbott Laboratories

SWOT Analysis
Abbott Laboratori
es
S W
O T
Strengths
Opportunities
Weakness
Threats

Future Opportunity

Additional growth opportunities participants should aim to secure include:

About Us
Copyright © PROPHECY 2019, All Rights Reserved 61
Disclaimer
 The material is based on sources which we believe are reliable, but no warranty, either expressed or implied, is provided in relation to
the accuracy or completeness of the information. The views expressed are our best judgment as of the date of issue and are subject to
change without notice. Prophecy Market Insights takes no responsibility for decisions made on the basis of these opinions.
 Any redistribution of this information is strictly prohibited. Copyright © 2019 Prophecy Market Insights pvt. Ltd , all rights reserved.
Legal and Copyright Notices
 While the editors endeavor to ensure the accuracy of all information and data contained in this Market Research Report, neither they
nor Prophecy Market Insights Pvt. Ltd. accept responsibility for any loss or damage (whether direct or indirect) whatsoever to the
customer or any third party resulting or arising there from.
 All rights reserved. No part of this publication may be reproduced or used in any form or by any means graphic, electronic or
mechanical, including photocopying, recording, taping, or information storage and retrieval systems without permission of the
publisher.
Disclaimer:
Prophecy market Insights Pvt. Ltd attempts to ensure that the information provided in our market research reports is as accurate and
complete as possible, the quantity of detailed information used and the fact that some of the information (which cannot always be verified
or validated) is supplied by third parties and sources not controlled by prophecy market Insights Pvt. ltd means that we cannot always
guarantee the accuracy, completeness or originality of the information in some reports, and we are therefore not responsible for any errors
or omissions in those reports. The recipients of these reports are responsible for determining whether the information contained therein is
sufficient for use and shall use their own skill and judgement when choosing to rely upon the reports

T H A N K
YOU
To know more about us, please visit our website:
www.prophecymarketinsights.com
For sales queries or new topics email us on:
sales@prophecymarketinsights.com
For other queries contact:
Shweta R
(Business Development)
Prophecy Market Insights
Email: shweta.r@prophecymarketinsights.com

U.S. Inflammatory Bowel Disease Market.pdf

Recommended

Recommended

More Related Content

Similar to U.S. Inflammatory Bowel Disease Market.pdf

Similar to U.S. Inflammatory Bowel Disease Market.pdf (20)

More from ankitakalvankar

More from ankitakalvankar (12)

Recently uploaded

Recently uploaded (20)

U.S. Inflammatory Bowel Disease Market.pdf